ClinicalTrials.gg
CompletedNCT06698172VRvisualUpdated Oct 21, 2026

Motor Performance Improvement After Visual Rehabilitation

An interventional study of Virtual Reality rehabilitation in Visual Field Loss, Balance and Brain Injury, sponsored by Instituto de Investigación Sanitaria Aragón. Completed at 1 site in Spain. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Instituto de Investigación Sanitaria Aragón · Not applicable, Interventional, and Treatment

How we know

Updated Oct 21, 2026Now CompletedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Brain Injuries with a site in Spain — 11 open to participants now, 13 under way, none of them phase 3. Brain Injuries · Spain.

Enrollment
12th of 30
30 · median 30
Started
2024
with 4 others
No phase
27 of 43
8 open now
Registered
31st of 43
by date

Among the 43 studies in Brain Injuries with a site in Spain, this one is the 12th largest by enrollment of the 30 interventional ones that give a count, is one of 5 that started in 2024, is one of 27 with no phase, and was the 31st registered.

Brain Injuries

947 studies on the registry are indexed under Brain Injuries; 234 are open to participants now.

Browse Brain Injuries studies →

Open to participants now

11 of the 43 studies in Brain Injuries with a site in Spain are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 152 Brain Injuries studies recruiting now, 77 (51%) set no upper age limit and 53 (35%) stop at 75 or younger; 38 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Brain Injuries with a site in Spain, or all of them as a file.
02

Study summary

Acquired brain injury" refers to brain damage that impacts neurological processing, making daily activities challenging and often causing vision issues like binocular dysfunction, oculomotor problems, and visual field loss. In Spain, visual rehabilitation is limited, although it is more common in other countries.

These patients generally need an interdisciplinary approach involving professionals like physiotherapists and optometrists and often face mobility, balance, and spatial perception difficulties. Treatment tools include lenses, prisms, and technologies like virtual reality (VR). The Visionary VR program, presented by Dr. Portela, has shown promising results in visual field recovery by stimulating the affected area.

Visual rehabilitation is based on brain plasticity and involves three key strategies:

Prisms to expand the visual field. Compensatory therapy to improve eye movement. Restitution therapy to restore the visual field.

Read the detailed description

Acquired brain injury is a term that covers all brain damage, and it is common for such an injury to have a profound effect on neurological processing. This can negatively impact how a person performs their daily activities. Many of these patients experience various vision problems alongside general health deterioration. A high percentage of individuals exhibit deficits in binocular fusion, oculomotor dysfunctions, and visual field loss (Ciuffreda, 2007). While visual rehabilitation for these patients is common in other countries, in Spain, these treatments within rehabilitation are usually only carried out occasionally.

Acquired brain injury can be due to various causes, including strokes, trauma, and tumours. It should be noted that due to the aging population, the number of strokes increases every year, and mortality from this cause is decreasing, leading to a growing number of patients with sequelae. Patients with brain injury may require rehabilitation treatment from various professionals, including physiotherapists, occupational therapists, speech therapists, and optometrists. Treatment in these cases should be interdisciplinary, considering the multiple disabling conditions these patients suffer from.

Since acquired brain injury can affect any area of the visual system, a rigorous evaluation of vision is necessary, paying attention to ocular health, visual function, motor function and binocular system, oculomotor skills, accommodative state, and the integrity of the visual field (Callahan, 2003).

In addition to visual field loss, patients with hemianopia may suffer from symptoms such as dizziness, vertigo, or nausea. There is also an increased risk of falls due to mobility issues, posture problems, gait variability, and balance, as well as difficulty navigating obstacles. Alterations in body schema and location can also occur, with this altered spatial perception impacting motor coordination, orientation, and object location (Kotecha, 2013).

Visual field loss can take different forms, including central loss, hemianopia, quadrantanopia, and altitudinal loss. Hemianopia refers to the loss of half the visual field, either right or left. Depending on the area of the visual pathway where the lesion occurs, bitemporal hemianopia, homonymous hemianopia, or superior/inferior quadrantanopia can develop. Quadrantanopia refers to the loss of a quadrant of the visual field. Visual field tests provide relevant information about the location of the brain lesion in these cases (Ruddy, 2022).

Furthermore, certain visual conditions are often overlooked, especially if they are mild, such as non-strabismic binocular vision dysfunctions, accommodative deficits, or ocular motility issues. If not considered, they can act as obstacles in the patient's rehabilitation, preventing them from performing various daily activities. Patients may sometimes suffer from diplopia, photophobia, or blurred vision, but in many cases, it is the difficulties they encounter in performing certain activities that indicate the presence of a visual problem. In patients with traumatic brain injury, it is estimated that 69% had at least one visual problem, mainly affecting accommodation, convergence, and ocular motility (Armstrong, 2018).

A stroke can cause some patients (20% to 57% of stroke patients) to lose the ability to see the entire space in front of them, often losing a whole half of the normal visual field. Ocular movement disorders can affect more than 70% of stroke patients, resulting in difficulties in maintaining both eyes in their normal position when looking straight ahead or in moving the eyes correctly to look in a different direction. This can affect the patient's depth perception, make it difficult to perceive the complete environment, and severely impact their reading ability.

These patients can benefit from visual treatment through compensatory lenses, compensatory prisms, visual field treatment, filters for photosensitivity, and visual rehabilitation aimed at improving the compromised visual skills. These treatments can be proposed in isolation or in combination during the patient's rehabilitation process (Armstrong, 2018; Thiagarajan, 2014; Thiagarajan, 2013; Gallaway, 2017).

Prisms are often used for fusional problems when the patient experiences diplopia or has difficulties performing convergence or divergence movements. They are also useful for visual field loss, projecting the image from the affected side of the visual field to the intact side. In this case, their goal is to expand or relocate the affected visual field, and they can be adapted binocularly or monocularly, either sectorially or across the entire lens.

Additionally, in the past year, Dr. Juan Portela, an optometrist, presented a novel treatment with a visual rehabilitation program using Virtual Reality at the II Neuro-Ophthalmology Conference in Valencia and the VII Low Vision Conference in October in Zaragoza. He achieved remarkable results in several patients with visual field loss using the Visionary virtual reality program (Visionary Sport, Gijón, Spain), increasing the visual field with stimuli appearing at the limit of the affected field area. This field restoration is reflected in visual field tests with fixation control in patients with hemianopia and altitudinal defects, which could have been caused by traumatic brain injury or stroke, even years before starting the Virtual Reality treatment. During the treatment, patient fixation was monitored using an eye tracker to control involuntary saccadic movements (Portela, 2023).

Previously, Casco et al. conducted a study using visual rehabilitation with Gabor patches in 10 patients with homonymous visual field defects for over six months, finding a significant improvement in the visual field, although it was approximately 5 degrees. The restored area improved letter recognition and the perception of moving shapes (Casco, 2018). Portela appears to have achieved better results in the cases he recently presented at several conferences.

Brain plasticity is the basis of visual rehabilitation, aiming to enhance the patient's visual skills and improve their quality of life as much as possible. The brain and its neural connections strengthen with the use of functions that depend on them. Visionary offers a set of exercises designed to rehabilitate deficits in visual tracking and binocular vision through perceptual learning. The Visionary software has been used in other studies related to visual rehabilitation in patients with amblyopia and limited stereopsis (Portela-Camino, 2018; Portela-Camino, 2021; Molina-Martín, 2020).

It is important to consider that there are three main strategies in the rehabilitation of patients with peripheral visual field loss, which can also be used in combination:

  • Optical or substitution therapy using prisms. The goal is to expand the visual field by shifting part of the affected visual field to the healthy side of the field using the prism. Various strategies exist for this.
  • Oculomotor or visual compensation therapy aims to enhance the patient's residual visual skills, improving the quality of ocular motility. This method helps the patient improve environmental scanning, first statically and then dynamically, with the ultimate goal of improving mobility. Visual-assisted therapy enhances outcomes for stroke patients with homonymous hemianopia alone or combined with oculomotor dysfunction. Visual therapy increased peripheral visual awareness. Additionally, patients felt safer in traffic and outdoor activities. Reading speed significantly increased, and the ability to keep a moving object in focus improved (Smaakjær, 2018).
  • Visual field restitution therapy is based on cortical plasticity theories and the possibility of restoring the affected visual field (Casco, 2018).

The main objective of this project is to evaluate motor and balance improvement in patients with acquired brain injury and to analyse the improvement in the visual field following treatment with Virtual Reality.

03

Conditions studied

  • Visual Field Loss
  • Balance
  • Brain Injury
  • Motor Performance

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult subjects diagnosed with acquired brain injury either from a stroke or trauma.
  • Subjects without cognitive impairment.
  • Subjects without pre-existing musculoskeletal disorders prior to the acquired brain injury.
  • Subjects without hemineglect.
  • Subjects with more than 6 months of progression since the brain injury.
  • Subjects who have an electronic device such as a computer and internet access to perform the exercises at home.
  • Subjects with altitudinal visual field loss, hemianopia, or quadrantanopia with the central field preserved and at least 0.5 visual acuity.

Exclusion criteria

Exclusion Criteria:

  • Not signing the .
  • Previous severe mental pathology to eliminate possible confounding factors if their daily activities are already affected.
  • Uncontrolled epilepsy.
  • Subjects with glaucoma or retinal pathologies affecting the visual field.
  • Subjects with previous ocular surgery (cataract or refractive surgery) with less than 6 months of progression.
  • Subjects who are not stable in any associated clinical pathology or otherwise diagnosed.
  • Subjects who have previously undergone visual rehabilitation for the field defect.
  • Not performing the proposed home exercises.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    VR Study Group

    Once the patient is included in the study, 12 weekly sessions of visual rehabilitation, each lasting 45 minutes, will be scheduled. A Virtual Reality device will be used along with the Visionary Sport visual therapy software.

    Other: Virtual Reality rehabilitation

Interventions

  • OtherVirtual Reality rehabilitation

    The study includes 12 weekly 45-minute visual rehabilitation sessions using a Virtual Reality device with Visionary Sport software. Originally designed for sports visual training, this software features gamified exercises to improve visual response times under professional supervision. Activities include games to enhance fixation, ocular motility, peripheral vision, and vergence. The "Peripheral Attention" activity trains reaction times to static stimuli perceived in the peripheral retina, adjustable to the patient's visual field defect. Stimuli can be placed at 10, 20, or 30 degrees in the peripheral field. The VR headset (Vive Focus 3) includes an eye tracker to monitor and adapt stimuli based on patient performance. Patients also perform 30 minutes of daily exercises at home, using proprietary software and Tobii 4C and 5C eye-tracking devices for ocular monitoring.

06

What researchers measure

Primary outcomes

  1. Visual field

    The threshold test will be used in a 30-2 field size with fixation monitoring.

    Time frame: 15 minutes

  2. Balance

    The stabilometric study will be conducted using the Podoprint® pressure platform (Grupo Namrol, Barcelona, Spain). A balance assessment will be conducted after 6 sessions and after 12 sessions of treatment.

    Time frame: 15 minutes

Secondary outcomes

  1. Visual Acuity

    Measurement of visual acuity in near and distance vision

    Time frame: 2 minutes

  2. Subjective refraction

    Evaluation of subjective refraction using trial lenses

    Time frame: 5 minutes

  3. Worth test

    The Worth Four Light Test is a clinical assessment of binocular vision, evaluating diplopia and suppression. The patient views a flashlight with four illuminated dots in a diamond pattern: one red at the top, two green on the sides, and one white at the bottom. The test is conducted at both 40 cm and 6 m distances.

    Time frame: 1 minute

  4. Ramdom Dot 2

    This test is used to measure the patient's stereopsis between 900" and 12.5".

    Time frame: 2 minutes

  5. Cover Test

    The test requires the patient to focus on both a distant object and a near object at different times during the examination. An eye is covered briefly, then uncovered while observing any movement in both eyes. The cover test helps identify the type of ocular deviation and measures the degree of misalignment.

    Time frame: 1 minute

  6. Maddox rod test

    The Maddox rod test is a subjective method for detecting and measuring latent or manifest strabismus by projecting a red line to one eye and a white light to the other, using prisms to determine the angle and amount of deviation.

    Time frame: 1 minute

  7. Near point of convergence

    The convergence test assesses a person's ability to focus on a near object, observing when diplopia (double vision) occurs and noting the point at which both eyes regain focus as the object is moved away.

    Time frame: 2 minutes

  8. Fusional vergences with prism bars

    Fusional vergence was evaluated using a horizontal prism bar ranging from 1 to 40 prism diopters (pd) for both distance (6 m) and near fixations (40 cm). A single Snellen letter at the 6/12 level served as the fixation target for both distances. Prism strength was gradually increased, and patients indicated when the target appeared double. This prism strength was recorded as the break point, confirmed by the examiner as an exotropia without motor fusion recovery. The prism power was then reduced until the patient regained single vision, marking the recovery point. Both convergence and divergence break and recovery points were measured using base-out (BO) and base-in (BI) prisms, respectively.

    Time frame: 4 minutes

  9. Accommodative amplitude

    The amplitude of accommodation will be measured using the push-up and push-down methods. It will be conducted in non-presbyopic patients.

    Time frame: 1 minutes

  10. Accommodative facility test

    Monocular and binocular near accommodative facility will be measured using ±2.00 DS flipper at 40 cm. It will be conducted in non-presbyopic patients.

    Time frame: 3 minutes

  11. NSUCO test (Northeastern State University College of Optometry's Oculomotor test)

    The NSUCO test assesses the quality of saccadic and pursuit eye movements. It provides a quick analysis with minimal patient cooperation. The setup involves two small colored reflective spheres (approximately 1/2 cm in diameter) on dowel sticks-one for pursuit and two for saccades.

    Time frame: 2 minutes

  12. DEM test (Developmental Eye Movement test )

    The DEM test evaluates the speed and accuracy of a participant's ability to read numbers in vertical and horizontal formats. It consists of a pretest and three test cards: two vertical subtests (A and B) with single-digit numbers, and one horizontal subtest (C) with more numbers in varying distances. The time taken for each subtest is recorded, and the ratio of horizontal to vertical time helps diagnose oculomotor dysfunction or difficulties in rapid automated naming.

    Time frame: 3 minutes

  13. DIVE device (Device for an Integral Visual Examination)

    The DIVE device (Device for an Integral Visual Examination) is a digital tool developed to assess various aspects of visual function, particularly in children, including infants as young as six months and those with developmental challenges. It presents specialized visual stimuli on a high-resolution screen and uses eye-tracking technology to gather precise gaze data, allowing for automated and objective visual assessments.

    Time frame: 3 minutes

  14. Lawton and Brody Scale for Instrumental Activities of Daily Living (IADL)

    The questionnaires will be applied to assess quality of life and daily activities before and after the intervention. Lawton and Brody Scale for Instrumental Activities of Daily Living (IADL) measures the degree of independence.

    Time frame: 3 minutes

  15. Barthel Index

    The questionnaire will be applied to assess quality of life and daily activities before and after the intervention. • Barthel Index: Measures the ability of a person to perform ten daily activities, providing a quantitative estimate of their degree of independence. Scores range from 0 to 100, with lower scores indicating more dependence.

    Time frame: 3 minutes

  16. WHOQOL-BREF Questionnaire

    The questionnaire will be applied to assess quality of life and daily activities before and after the intervention. • WHOQOL-BREF Questionnaire: A self-administered instrument that provides a profile of perceived quality of life, consisting of 26 questions developed from the original 100-section version (Whoqol-100).

    Time frame: 3 minutes

07

Study locations

1 site
  • University of Zaragoza
    Zaragoza, Zaragoza 50009, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2024 to primary completion in Jul 2026, 20 months.

Of 285 non-industry interventional studies with no phase under Brain Injuries, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's 20 months is below that.

Counting every sponsor, half of 298 studies reached it within 24 months; a quarter within 12 and three quarters within 48.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: primary completion Oct 2025 → Jul 2026 and completion Dec 2025 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2024
First posted
Nov 20, 2024
StartActual
Nov 29, 2024
Primary completionActual
Jul 31, 2026was Oct 2025
CompletionActual
Sep 30, 2026was Dec 2025
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 21, 2026
Sites
1 site added, 2 sites removed
Show site
  • University of Zaragoza · Zaragoza, Spain
Show 2 removed
  • University of Zaragoza · Zaragoza, Spain
  • University of Zaragoza · Zaragoza, Spain
Oct 21, 2026
Primary completion
Oct 31, 2025→Jul 31, 2026 (actual)
Oct 21, 2026
Study completion
Dec 31, 2025→Sep 30, 2026 (actual)
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Recruiting→Completed
    1 site added, 2 sites removed
    Show site
    • University of Zaragoza · Zaragoza, Spain
    Show 2 removed
    • University of Zaragoza · Zaragoza, Spain
    • University of Zaragoza · Zaragoza, Spain
    Primary completion Oct 31, 2025→Jul 31, 2026 (now actual)
    Study completion Dec 31, 2025→Sep 30, 2026 (now actual)
    + 5 other changes: identifiers, verification date, oversight details, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06698172
Lead sponsor
Instituto de Investigación Sanitaria Aragón
Responsible party
Carmen Lopez (Ph.D. from the University of Zaragoza, Universidad de Zaragoza) — Principal investigator
First posted
Nov 20, 2024
Start date
Nov 29, 2024
Primary completion
Jul 31, 2026
Completion
Sep 30, 2026
Last update
Oct 21, 2026

Study contacts

Maria José López de la Fuente, PhD
study chair · Universidad de Zaragoza
Jorge Pérez Rey, PhD
study chair · Universidad de Zaragoza
Naiara Díaz Marín, MSc
study chair · Universidad de Zaragoza
Javier Mateo Gabás, PhD
study chair · Universidad de Zaragoza

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion